6–8 week old HHDII-DR1 mice were immunized with plasmid DNA or peptides as we have previously reported (22 (link),24 (link)). For tumor protection studies, HHDII-DR1 mice were immunized intradermally six times biweekly with 100 μg of native or modified SSX2 vaccines followed two weeks later by subcutaneous inoculation with 2×104 SSX2- or GFP-expressing sarcoma cells in contralateral flanks. Tumor-cell suspensions were prepared in 50% High Concentration, LDEV-Free Matrigel (BD Biosciences, San Jose, CA). Tumor volume was measured in cubic centimeters according to the following formula: (π/6)(long axis)(short axis)2. For tumor therapy studies, animals were first inoculated with tumor cells followed by weekly vaccination beginning one day after tumor implantation. In tumor studies using PD-1/PD-L1 blocking antibodies, 100 μg of antibody (or IgG isotype control, BioLegend, San Diego, CA) was injected intraperitoneally on the day following each vaccination.
Ldev free matrigel
Manufactured by BD
Sourced in United States
LDEV-Free Matrigel is a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma. It is free of detectable levels of the laminin-binding protein laminin-entactin complex (LDEV). LDEV-Free Matrigel provides a reconstituted basement membrane complex that can be used for various cell culture applications.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using ldev free matrigel
1
Intradermal SSX2 Vaccine for Sarcoma
2
Establishment of Patient-Derived Xenograft Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This procedure was approved by the Stanford University's Research Compliance Office on Human Subjects Research and IRB, as well as Stanford's Administrative Panel on Laboratory Animal Care (APLAC). Informed written consent was obtained from the patient and fresh tumor tissue was taken at the time of surgical excision. The sample was placed in ice cold RPMI 1640 medium supplemented with penicillin/streptomycin and 10% heat-inactivated FBS (Invitrogen-Life Technologies, Carlsbad, CA, USA) as previously described by our group [47 (link)]. One to two mm fragments were mixed with LDEV-free Matrigel (BD Biosciences, San Jose, CA, USA) and orthotopically implanted into the MFPs of 5 female NOD SCID mice (NOD. CB17-Prkdcscid/J, Jackson Laboratory West, Sacramento, CA, USA). Mice were housed in a pathogen-free animal environment. Once established, PDOX tumors were expanded by passaging from mouse to mouse. After a second passage, one PDOX tumor was fixed in formalin and embedded in paraffin for immunohistochemical studies.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!